RCT: New blood test could improve prostate cancer screening.

Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

News release: New blood test improves prostate cancer screening – Karolinska Institutet

Related:

RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.

Commentary on Twitter

Online first: #Prostatecancer #screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial #pcsm https://t.co/bijoJk8RbK pic.twitter.com/ENWEjqG3Kr

— The Lancet Oncology (@TheLancetOncol) August 13, 2021